Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | $251.00K | $33.49M | $4.93M | $2.00M | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $251.00K | $33.49M | $4.93M | $2.00M | N/A |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% |
| Operating Expenses | $67.53M | $64.16M | $64.76M | $55.27M | $18.27M |
| Operating Income | $-67.28M | $-30.67M | $-59.83M | $-53.27M | $-18.27M |
| Operating Margin | -26805.58% | -91.58% | -1213.32% | -2660.94% | 0.00% |
| Net Income | $-58.49M | $-27.70M | $-58.39M | $-71.83M | $-17.99M |
| Net Margin | -23303.98% | -82.69% | -1184.10% | -3587.66% | 0.00% |
| EPS (Basic) | $-5.20 | $-1.19 | $-3.32 | $-4.08 | $-1.02 |
| EBITDA | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A |